COSCIENS Biopharma Inc. (TSX:CSCI)

Market Cap	14.85M
Revenue (ttm)	12.98M
Net Income (ttm)	-25.24M
Shares Out	3.15M
EPS (ttm)	-8.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,052
Average Volume	1,909
Open	4.61
Previous Close	4.61
Day's Range	4.61 - 5.09
52-Week Range	2.90 - 15.13
Beta	1.86
RSI	51.96
Earnings Date	May 9, 2025

About COSCIENS Biopharma

COSCIENS Biopharma Inc., a life science company, engages in developing and commercializing products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Columbia, the United Kingdom, and internationally. The company lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone defici...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 40
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CSCI

Financial Performance

In 2024, COSCIENS Biopharma's revenue was $9.59 million, an increase of 34.22% compared to the previous year's $7.14 million. Losses were -$15.31 million, 339.3% more than in 2023.

Financial numbers in USD